Qiagen

The firm said it can produce enough viral RNA extraction reagents to support more than 7 million real-time PCR tests per month for detecting SARS-CoV-2.

The partners will specifically integrate Gilson's Trackman Connected digital bench tools and Qiagen's manual nucleic acid extraction kits.

The company had announced on March 3 that the lenders had committed to the debt financing in connection with its proposed acquisition of Qiagen.

The PCR-based tests, which detect SARS-CoV-2 nucleic acid, are limited to use in the labs where they were developed, according to the FDA.

Preliminary Q1 revenues and EPS benefitted from product sales for COVID-19 testing and significantly exceeded previously issued guidance.

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

The NeuMoDx SARS-CoV-2 Test Strip can run on the firm's fully-automated mid- or high-throughput instruments.

The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.

Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.